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ABSTRACT
KRAS mutation is often present in many hard-to-treat tumors such as colon 
and pancreatic cancer and it is tightly linked to serious alterations in the normal cell 
metabolism and clinical resistance to chemotherapy.
In 1931, the winner of the Nobel Prize in Medicine, Otto Warburg, stated that 
cancer was primarily caused by altered metabolism interfering with energy processing 
in the normal cell. Increased cell glycolytic rates even in the presence of oxygen is 
fully recognized as a hallmark in cancer and known as the Warburg effect.
In the late 1970's, Linus Pauling and Ewan Cameron reported that vitamin C 
may have positive effects in cancer treatment, although deep mechanistic knowledge 
about this activity is still scarce.
We describe a novel antitumoral mechanism of vitamin C in KRAS mutant 
colorectal cancer that involves the Warburg metabolic disruption through 
downregulation of key metabolic checkpoints in KRAS mutant cancer cells and tumors 
without killing human immortalized colonocytes.
Vitamin C induces RAS detachment from the cell membrane inhibiting ERK 1/2 
and PKM2 phosphorylation. As a consequence of this activity, strong downregulation 
of the glucose transporter (GLUT-1) and pyruvate kinase M2 (PKM2)-PTB dependent 
protein expression are observed causing a major blockage of the Warburg effect and 
therefore energetic stress.
We propose a combination of conventional chemotherapy with metabolic 
strategies, including vitamin C and/or other molecules targeting pivotal key players 
involved in the Warburg effect which may constitute a new horizon in anti-cancer 
therapies.
INTRODUCTION
The KRAS proto-oncogene encodes a ~21 kDa 
small GTPase, which cycles between GTP-bound active 
and GDP-bound inactive states. Mutated KRAS is reported 
in approximately 35%-45% of colorectal cancers and 
>90% of pancreatic ductal adenocarcinoma (PDAC) [1, 2]. 
Molecular evidences support the master role of oncogenic 
KRAS disrupting the metabolic homeostasis via alteration 
of glucose uptake, glycolytic flux, and glutamine usage in 
colon and pancreatic tumors that often display very high 
resilience to chemotherapy [3].
Quest for new scopes and molecules capable to 
overcome chemotherapy resistance in tumors displaying 
gene mutations downstream EGFR is a top priority in 
oncological research worldwide.
               Research Paper
Oncotarget47955www.impactjournals.com/oncotarget
In 1976, Linus Pauling and Ewan Cameron 
performed a clinical study of the survival times of 100 
terminal cancer patients who were given supplemental 
ascorbate, usually 10 g/day, and 1000 matched controls, 
similar patients who had received the same treatment 
except for the ascorbate. Survival times greater than 1 yr 
after the date of untreatability were observed for 22% of the 
ascorbate-treated patients and for 0.4% of the controls [4].
Many authors have reported that vitamin C shows 
certain antitumoral activity, but the molecular mechanism 
underlying this killing effect and the intriguing selective 
activity displayed is far from clear.
Recently, Yun J et al., have recently presented 
noteworthy data stating that oxidized vitamin C is able to 
kill CRC cells depending on the KRAS mutational status 
[5]. Interestingly, previous works carried out by Chen Q 
et al., supporting the previous clinical study carried out by 
Pauling and Cameron, have shown that vitamin C exerts 
killing effects on cancer cells from very different origin, 
displaying a wide variety of gene mutations (many of them 
do not display KRAS mutation) and alterations in different 
signaling pathways [1, 6]. It strongly suggests that 
although KRAS status is important to explain the killing 
effect of vitamin C, there must be other mechanisms 
underlying its role in cancer.
Hanahan and Weinberg [7], stated that six essential 
hallmarks in cell physiology could enhance malignant 
cell growth 1) self-sufficiency in growth signals, 2) 
insensitivity to growth inhibitory signals, 3) evasion of 
programmed cell death (apoptosis), 4) limitless replicative 
potential, 5) increased vascularity (angiogenesis), and 6) 
tissue invasion and metastasis.
However, another abnormality in cell homeostasis 
is currently considered as the seventh hallmark in cancer.
Biochemist Otto Warburg received the Nobel Prize 
in 1931 showing that, contrary to normal cell metabolism, 
which primarily rely on mitochondrial oxidative 
phosphorylation to generate ATP, most cancer cells show 
increased glycolysis rate. This phenomenon is termed the 
Warburg effect and it is a hallmark in cancer [8].
Nevertheless, the hypothesis that rocked the 
scientific community was his assertion that the prime cause 
of cancer is the replacement of the oxygen respiration in 
normal body cells by a fermentation of sugar [9].
Warburg hypothesized that cancer was caused by 
defects in mitochondrial oxidative phosphorylation and 
then forcing the cell to switch into glycolysis, thus cells 
would become undifferentiated and cancerous.
However, studies carried out by prof. Craig 
Thompson laboratory at the Memorial Sloan-Kettering 
Cancer Center, preferentially indicates that the Warburg 
effect is not just a passive response to damaged 
mitochondria but results from oncogene-directed 
metabolic reprogramming required to support glycolytic 
metabolism and anabolic growth [10].
The question about altered metabolism as primary 
cause or consequence in cancer still remains open.
Alterations of EGFR/MAPK signaling are frequently 
observed in KRAS and BRAF colon cancer correlating with 
chemoresistance and poor clinical outcome. Furthermore, 
mutations in EGFR/MAPK pathway and associated 
resistance to anti-EGFR therapies are, in fact, linked to 
the metabolic alterations described by Otto Warburg in 
cancer cells.
In this regard, Makinoshima H et al., published 
data showing that epidermal growth factor receptor 
(EGFR) signaling actually regulates global metabolic 
pathways in EGFR-mutated lung adenocarcinoma [11]. 
They demonstrated that EGFR-tyrosine kinase inhibitors 
(TKIs) were able to decrease lactate production, glucose 
consumption, and the glucose-induced extracellular 
acidification rate (ECAR), indicating that EGFR signaling 
was responsible for maintaining cell aerobic glycolysis 
observed in the Warburg effect. As it has been stated 
before, molecular evidences strongly support the role of 
oncogenic KRAS disrupting the normal cell metabolism 
in tight correlation to tumor resilience to anti-EGFR 
chemotherapy [1].
Anti-cancer strategies based on molecules targeting 
crucial enzymes involved in tumoral aerobic glycolysis, 
may help to overcome anti-EGFR resistance in cancer 
improving the response of those patients to conventional 
chemotherapy.
Here we present data describing a novel antitumoral 
mechanism of vitamin C that involves straight inhibition 
of constitutively activated EGFR/MAPK pathway in 
KRAS mutant CRC, which in turn provokes the stalling of 
the Warburg metabolism.
RESULTS AND DISCUSSION
Vitamin C selectively kills KRAS mutant 
colon cancer cells alone or in combination with 
cetuximab
We aimed to check out whether vitamin C could 
have some antitumoral activity in chemoresistant 
CRC in assays carried out using SW480 and LoVo cell 
lines, displaying KRAS mutations and no sensitivity to 
cetuximab.
SW480, LoVo cancer cells both harboring 
KRAS mutation (G12V and G13D respectively) and 
immortalized human colonocytes (HCEC) (KRAS wild 
type) were exposed to ascorbate for 2 h to mimic clinical 
pharmacokinetics, and the effective concentration that 
decreased survival to 50% (EC50) was determined. 
Observed EC50 was ≤ 10mM for both tumor cells lines 
tested. Remarkably, significative cytotoxicity in HCEC 
cells treated with 10 mM ascorbate was not detected 
(Figure 1A–1B). Mortality observed for both cancer cell 
lines was ≥ 60% just 36 h. after treatment (Figure 1C), 
although HT29 displayed more resistance to ascorbate.
We conclude that the effect of vitamin C seems to 
be, at least in part, dependent on the mutational status of 
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KRAS as previously stated by Yun J et al. [5]. Interestingly, 
KRAS mutation has been demonstrated to drive aberrant 
changes in the cell metabolic homeostasis in colon and 
pancreatic tumors [12, 13].
Therefore, assuming that vitamin C is targeting 
cells displaying abnormal metabolism, it might help to 
overcome anti-EGFR monoclonal antibody cetuximab 
(Erbitux) resistance in tumors harbouring mutated KRAS.
In order to demonstrate this hypothesis we used 
colon cancer cell lines HT29 (wild type KRAS), LoVo and 
SW480 (both displaying different KRAS mutations) were 
treated with cetuximab (HT29 calculated IC50=0,4 μM). As 
described, mutations in codon 12 or 13 in the KRAS gene 
Figure 1: Vitamin C selectively kills wild type and mutant KRAS colon cancer cells alone or in combination with 
cetuximab. A. apoptosis-inducing activities of vitamin C for Normal human immortalized Colonocytes (HCEC) and SW480 and LoVo 
cancer cell lines were annalyzed by Annexin-PI assay. Each cell line (2,3 105 cells) was incubated with vitamin C (10 mM) and PBS for 
controls. for 20 hr, apoptosis in each cell line was measured by staining with FITC-conjugated Annexin-V and Propidium Iodide (PI) 
using a Sigma-Aldrich Apoptosis kit. The populations of cells (annexin-V positive/PI negative) and late apoptotic cells (PI positive) as a 
percent of total cells were evaluated. Vitamin C displayed a selective killing effect on SW480 and LoVo. One-way ANOVA followed by 
Dunnett’s post-test for multiple comparisons. *p< 0.05, **p < 0.001, n = 3. B. vitamin C treatment at different concentrations were carried 
out with LoVo and SW480 cancer lines. SW480 and LoVo CRC lines were exposed to ascorbate at 2, 5 and 10mM, for 20 hr. Then, cells 
were tripsinized and fixed with trypan blue solution (Sigma-Aldrich). The effective concentration that decreased survival 50% (EC50) 
was determined. EC50 was <10 mM for both tumor cells tested. Cell counting was carried out using a TC20™ Automated Cell Counter 
(Biorad). One-way ANOVA followed by Dunnett’s post-test for multiple comparisons. *p < 0.05, **p < 0.001, n = 3. C. SW480 and LoVo 
cells were treated with vitamin C (7mM) for 5, 12 and 36 hr. Then, cells were tripsinized and fixed with trypan blue solution (Sigma-
Aldrich). Cell counting was carried out using a TC20™ Automated Cell Counter (Biorad). One-way ANOVA followed by Dunnett’s post-
test for multiple comparisons. *p < 0.05, **p < 0.001, n = 3. D. HT29 harboring wild type KRAS, and the KRAS mutants LoVo and SW480 
were treated with cetuximab (calculated IC50=0,4 μM), vitamin C (5mM) alone and combination for 12 hr. Then, cells were tripsinized and 
fixed with trypan blue solution (Sigma-Aldrich). Cell counting was carried out using a TC20™ Automated Cell Counter (Biorad). One-way 
ANOVA followed by Dunnett’s post-test for multiple comparisons. *p < 0.05, **p < 0.001, n = 3. Combination of both vitamin C and the 
anti-EGFR antibody cetuximab displayed a higher killing effect in the three lines tested.
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downstream of the EGFR induce constitutive activation 
of the RAS/RAF/MAPK pathway linked to resistance to 
anti EGFR therapies. Nevertheless, a retrospective study 
reported partial response to cetuximab in patients with 
KRAS G13D mutation [14]. As expected, neither LoVo 
nor SW480 cells did exhibit any sensitivity to cetuximab 
(Figure 1D). However, wild type KRAS HT29 cell growth 
was clearly inhibited by cetuximab to 52%.
The three CRC cell lines tested displayed differential 
sensitivity to pharmacological concentration of vitamin C 
(5mM). Again, HT29 colon cancer cells appeared to be 
more resistant to the cytotoxic activity of vitamin C than 
SW480 and LoVo.
Remarkably, treatment of HT29, SW480 and 
LoVo cells with cetuximab (0,4 μM) and vitamin C 
(5mM) abolished cell growth in the three lines tested. 
Combination of both, cetuximab and vitamin C was 
more effective than vitamin C alone, strongly suggesting 
that vitamin C may synergize with cetuximab via some 
molecular mechanism not yet described but likely 
involving metabolic targeting.
In order to support the in vitro data, we generated 
SW480 xenografts harboring KRAS mutation (G12V) 
in athymic nude mice Foxn1nu. Mice were treated 
with intraperitoneal (i.p) vitamin C at pharmacological 
concentration (4gr/kg body weight) once daily. 
Remarkably, in vivo experiments showed that using 
parenteral ascorbate as unique treatment, tumor growth 
was strongly reduced by 49 % (P = 0.007) (Figure 4B) 
thus supporting data obtained in our in vitro assays.
Some CRC patients displaying the KRAS G13D 
mutation may respond to cetuximab, so the question 
whether combinative dosage of vitamin C plus cetuximab 
could be even more effective in this type of tumors would 
need further research.
MAPK/EGFR pathway is selectively inhibited by 
vitamin C in KRAS mutant colon cancer
The observation that HT29 with wild type KRAS 
was less sensitive to vitamin C activity than the KRAS 
mutant cell lines SW480 and LoVo encouraged us to 
further examine the mechanism underlying putative 
interferences of vitamin C on MAPK/EGFR signaling 
pathway in both cetuximab-resistant cell lines.
Activated Extracellular-signal-Regulated Kinase 
1/2 (ERK1/2) is the key effector of the pathway. In 
fact, evidences that MAPK/ERK signaling induces cell 
proliferation, survival and cancer spreading, along with 
extreme frequency in which this pathway is aberrantly 
activated in cancer, support current investigations to 
identify new targets to inhibit ERK activation and other 
pathway intermediates [15].
KRAS/BRAF mutation status and also ERK1/2 
activation have been recently reported as biomarkers 
for chemoresistance in gastrointestinal cancer to agents 
such as 5-Fu, SN38 and Oxaliplatin [16]. Furthermore, 
activation of ERK1/2 is also responsible of induced 
chemoresistance of glioma cells to Temozolomide [17].
Outstandingly, western blot analysis displayed that 
vitamin C (5mM) treatment almost completely abolished 
ERK1/2 phosphorylation in both, SW480 and LoVo CRC 
lines without affecting ERK1/2 expression. Moreover, 
phosphorylation of ERK1/2 was hardly observable in 
normal human colonocytes (HCEC) with wild type KRAS 
(Figure 2A) after 20hr treatment. Dramatic inhibition 
of ERK1/2 phosphorylation was confirmed in vivo by 
immunohistochemistry assays in vitamin C-treated SW480 
xenografts (Figure 4C). generated in athymic nude mice 
Foxn1nu.
Upwards in the phosphorylation cascade, mitogen-
activated protein kinase kinase 1 (MEK1) expression and 
phosphorylation was also observed to be downregulated 
by vitamin C treatment in both cell lines tested. On 
the other hand, although MEK1 phosphorylation was 
detected in normal HCEC, neither protein expression nor 
phosphorylation were affected by vitamin C (Figure 2B).
The first step in the EGFR/MAPK phosphorylation 
cascade is the activation of KRAS. We wondered if 
vitamin C could target KRAS straightly in a way that 
could explain the alterations observed in ERK1/2 and 
MEK1 phosphorylation state.
To our surprise, double immunofluorescence 
assays carried out in LoVo cells using antibodies raised 
against human RAS and cytokeratin 20, displayed KRAS 
mislocalization from plasma membrane and colocalization 
with cytoplasmic cytokeratin (Figure 2C) after vitamin C 
treatment.
It is known that Ras proteins regulate signaling 
pathways important for cell growth, differentiation, and 
survival. Constitutive KRAS signaling activity depends on 
its level of enrichment on the plasma membrane [18]. As 
described, Ras trafficking to the cell plasma membrane is a 
multi-step process involving farnesylation of the cysteine 
residue of the RAS CAAX motif, methylation of the 
α-carboxyl group and finally, Ras proteins take one of two 
possible routes to the cell surface [19, 20].
So, we observed that vitamin C was able to induce 
RAS detachment from cell plasma membrane, but the 
question regarding the molecular mechanism underlying 
this observation needs to be addressed.
In 2010, Weinberg F et al., reported that 
mitochondrial metabolism allows for the generation of 
reactive oxygen species (ROS) which are required for 
Kras-induced anchorage-independent growth through 
regulation of the ERK/MAPK signaling pathway [21].
As it has been previously described, vitamin C is a 
potent intracellular ROS quencher [22]. So we performed 
assays using dichlorofluorescin diacetate (DCFDA), a 
fluorogenic dye that measures hydroxyl, peroxyl and other 
reactive oxygen species (ROS) activity within the cell, in 
order to check out ROS levels in SW480 and LoVo cells 
after vitamin C treatment. Interestingly, we detected that 
vitamin C treatment dramatically reduced intracellular 
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ROS levels in SW480 and LoVo cells (Figure 2D), thus 
vitamin C-ROS quenching hampers KRAS trafficking 
to the cell plasma membrane, then interfering with 
downstream RAS/ERK phosphorylation cascade.
Vitamin C downregulates the Warburg 
checkpoints GLUT-1 and PKM2 through 
inhibition of PKM2 phosphorylation at Ser 37
Malignant transformation of a normal cell into a 
cancer cell invariably correlates to metabolic alterations 
and high glucose intake. The Glucose transporter 1 
(GLUT1) catalyzes facilitative diffusion of glucose into 
the normal cell and it is often upregulated in many tumors 
fulfilling the high glucose requirements. Interestingly, 
GLUT-1 is considered as a master regulator of the Warburg 
effect during the neoplastic transformation [23]. GLUT-1 
can be employed as a molecular marker in CRC to indicate 
the tumor hypoxia degree [24], HIF-1 expression and 
resistance to chemotherapy [25, 26].
Therefore we aimed to check out GLUT-1 status 
in human colon cancer and to observe if vitamin C could 
Figure 4: Vitamin C inhibits tumor growth in SW480 xenografts generated in athymic nude mice Foxn1nu though 
downregulation of GLUT-1, p-ERK and PKM2. A. immunohistochemistry carried out in human normal colon mucosa (upper 
and bottom) and colon adenocarcinoma shows differential expression of GLUT-1 and PKM2. Vitamin C receptor (SLC23A1) shows no 
differential expression. Box-plot shows the relative expression of SLC23A1, GLUT-1 and PKM2 in normal colon mucosa and adenocarcinoma 
(upper and bottom crypt). Box represents 25th and 75th percentile expression and bar representsmedian. Whiskers corresponds to 5th 
and 95th percentile and outliers aremarked separately. B. tumor growth of SW480 KRAS (G12V) xenograft in female athymic nude mice 
(Foxn1nu, 7 weeks old). Suspensions of 2x106cells were injected subcutaneously in control and experimental mice. Animals were treated 
(i.p) with vehicle or vitamin C (4 gr/kg body weight) for 15 days once daily. Tumors were measured twice weekly in three perpendicular 
dimensions using a Vernier caliper and tumor volume was calculated. C. immunohistochemistry assays in SW480 tumors shows in vivo 
downregulation of PKM2, GLUT-1 and p-ERK in vitamin C-treated tumors.Box-plot shows the relative expression of GLUT-1, PKM2 and 
p-ERK in normal colon mucosa and adenocarcinoma (upper and bottom crypt). Box represents 25th and 75th percentile expression and bar 
Whiskers correspond to 5th and 95th percentile and outliers are marked separately.
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be able to regulate GLUT-1 expression in human KRAS 
mutant cancer cells and tumors.
Immunohistochemistry (IHC) assays carried out in 
normal human colon mucosa (upper and bottom crypts) 
and colon adenocarcinoma showed strong GLUT-1 
upregulation in CRC (Figure 4A). Interestingly, in the 
same experiment we did not detect tumor overexpression 
of vitamin C receptor SLC23A1.
SW480 and LoVo cancer cells were treated 
with pharmacological doses of vitamin C (5 mM) for 
5 and 20 hr and dramatic downregulation of GLUT-
1 protein was observed as showed in Western Blot and 
immunofluorescence assays (Figure 3A). Experiments 
performed using Quantitative PCR showed also 
significative downregulation of GLUT-1 mRA pointing 
out to a transcriptional (direct or indirect) regulation of 
GLUT-1 by vitamin C (Figure 3B). Impressive inhibition 
of GLUT-1 expression in tumors was also observed in vivo 
in vitamin C-treated murine SW480 xenografts (Figure 
4C). Therefore, data obtained strongly supports that 
vitamin C targets Warburg metabolism and it is able to 
interfere with the expression of crucial checkpoints in the 
neoplastic transformation.
However, in order to establish a molecular 
mechanism it is necessary a link between the effects of 
vitamin C in the MAPK/EGFR pathway and the observed 
GLUT-1 downregulation.
In 2012, Yang W et al., reported that aberrant EGFR 
pathway activation in human cancer cells induces PKM2 
nuclear translocation, which is mediated by Pyruvate 
kinase M2 (PKM2) phosphorylation at Ser37 by ERK. 
PKM2 (Ser37) is shuttled into the cell nucleus acting as a 
coactivator of β-catenin, inducing c-Myc expression which 
in turn upregulates the expression of glycolytic enzymes 
such as GLUT1 and LDHA [27].
Figure 2: Vitamin C hampers the EGFR/MAPK signaling pathway through KRAS detachment from the cell plasma 
membrane. A. western blot analysis of ERK1/2 and p-ERK1/2 expression in Normal Human immortalized Colonocytes (HCEC) and the 
KRAS mutant cell lines SW480 and LoVo treated with vitamin C (8 mM) for 20 hr. Beta-actin was employed as protein loading control. 
B. Western blot analysis of MEK1 and p-MEK-1 expression in Normal Human immortalized Colonocytes (HCEC) and the KRAS mutant 
cell lines SW480 and LoVo treated with vitamin C for 20 hr. C. LoVo cells were treated with treated with vitamin C for 20 hr. Double 
immunofluorescence with anti RAS (red) and cytokeratin 20 (green) raised antibodies shows cytoplasmic colocalization of both proteins 
after vitamin C treatment (8 mM). D. activity of vitamin C in quenching intracellular reactive oxygen species (ROS) was measured using 
a Cellular ROS/Superoxide Detection Assay Kit (Abcam). SW480 and LoVo CRC lines were exposed to ascorbate (7 mM) and PBS for 
controls for 20 hr. After treatment, cells were washed twice with PBS solution and then incubated in medium containing 10 μmol/l H2DCF-
DA at 37°C for 30 minutes. After incubation, cells were harvested by trypsinization, and intracellular levels of ROS were measured by 
fluorescence emission. Relative intracellular ROS levels after treatment with vitamin C were calculated in relation to control, which was 
given a value of 100. One-way ANOVA followed by Dunnett’s post-test for multiple comparisons. *p < 0.05, **p < 0.001, n = 3.
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PKM2 is upregulated in CRC providing tumor 
growth advantages [28, 29] contributing to gefitinib 
resistance via upregulation of STAT3 activation in 
colorectal cancer [30]. Therefore, PKM2 can be 
considered as a potential therapeutic target in colon and 
pancratic neoplasias.
In IHC assays we could confirm that PKM2 is 
upregulated in colon cancer when compared with normal 
mucosa (Figure 4A), therefore we aimed to check out 
any putative effect of vitamin C in PKM2 expression 
and phosphorylation in Ser 37 that could link GLUT-
1 downregulation with the observed inhibition of the 
MAPK/EGFR pathway.
Outstandingly, western blot analysis displayed 
inhibition not only of PKM2 but also p-PKM2 (ser37) 
in both KRAS mutant SW480 and LoVo cells (Figure 
3C–3D) and this observation could be confirmed in 
immunofluorescence assays using antibodies raised 
against PKM2 and p-PKM2 (ser37). Interestingly, in this 
occasion mRNA expression of PKM2 appeared to be 
unaffected by ascorbate treatment (data not shown).
We could also observe an in vivo PKM2 drastic 
inhibition in murine SW480 xenografts, thus correlating 
with reduced tumor growth after intraperitoneal vitamin 
C treatment.
Downregulation of GLUT-1 expression and 
PKM2 expression and phosphorylation at ser37 strongly 
corroborates the initial hypothesis, stating that vitamin C 
exerts its selective antitumoral activity targeting enzymes, 
signaling pathways and metabolic processes involved in 
the Warburg effect.
Figure 3: Vitamin C impairs the Warburg effect in KRAS mutant cells through downregulation of GLUT-1 and PKM2. 
A. immunofluorescence analysis of GLUT-1 expression in SW480 and LoVo cells after vitamin C treatment (8 mM) for 20 hr. Glucose 
receptor 1 (GLUT-1) is shown in green. Cell nucleus is depicted in blue after DAPI staining. B. western blot and Real Time Quantitative PCR 
analysis of GLUT-1 protein and mRNA expression in SW480 and LoVo cells after vitamin C treatment for 20 hr. C. immunofluorescence 
analysis of PKM2 and p-PKM2 expression in SW480 and cells after vitamin C treatment (5 mM) for 20 hr. PKM2 and p-PKM2 is shown in 
green. Cell nucleus is depicted in blue after DAPI staining. Western-Blot analysis of PKM2 and p-PKM2 expression in SW480 cells after 
vitamin C treatment for 20 hr. D. immunofluorescence analysis of PKM2 and p-PKM2 expression in LoVo cells after vitamin C treatment 
(8 mM) for 20 hr. PKM2 and p-PKM2 is shown in green. Cell nucleus is depicted in blue after DAPI staining. Western-Blot analysis of 
PKM2 and p-PKM2 expression in LoVo cells after vitamin C treatment for 20 hr.
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Physiological concentrations of vitamin C 
inhibits KRAS mutant colonosphere-formation 
downregulating c-Myc
Colonospheres derived from colon cancer cell lines 
usually show increased levels of total β-catenin inducing 
TCF/LEF transactivation and c-Myc overexpression that 
confers molecular features associated with resistance to 
drugs, radioresistance and poor clinical outcome [31].
Strikingly, vitamin C treatment on colonospheres 
derived from SW480 and LoVo CRC cell lines showed 
a drastic effect not only in colonosphere formation, 
but also in the number of cell per single sphere in both 
cases (Supplementary Figure 1A and 1B). However the 
most noticeable result is that the effect was observed at 
previously described human physiological concentrations 
of vitamin C (≤ 200 μM).
Interestingly, western blot analysis showed strong 
inhibition of c-Myc oncogene in colonospheres treated 
at concentrations of vitamin C as low as 100 μM, 
suggesting that vitamin C also could be interfering with 
the constitutively activated WNT pathway in colon cancer 
(Supplementary Figure 1C).
As it was said previously, there is a strong interplay 
between the two major signaling routes altered in colon 
cancer: EGFR/MAPK and WNT signaling pathway. We do 
think that vitamin C inhibition of PKM2 phosphorilation 
at serine 37 avoids PKM2 translocation to the cell nucleus, 
therefore stalling β-catenin-TCF/LEF dependent GLUT-
1 and c-Myc expression. In spite of this, straight activity 
of vitamin C in the regulation of WNT pathway partners 
cannot be ruled out.
PKM2 inhibition is mediated by vitamin C 
downregulation of polypyrimidine tract binding 
protein 1 (PTB1)
However, results obtained are not enough to explain 
the previously observed effect of vitamin C in PKM2 
protein dowregulation.
Polypyrimidine Tract Binding Protein 1 (PTB1) 
belongs to the subfamily of heterogeneous nuclear 
ribonucleoproteins (hnRNPs) and has been reported to 
regulate PKM2 alternative mRNA splicing [32]. IF and 
western blot assays displayed that PTB expression was 
clearly inhibited after 20 hr of vitamin C (5mM) after 
treatment (Supplementary Figure 2A and 2C) although 
no effect was observed at mRNA level (Supplementary 
Figure 2B). Interestingly, PTBP1 expression is controlled 
by the complex formed by β-catenin, TCF/LEF and 
nuclear PKM2 (Ser37). We have observed that vitamin C 
is capable to stall phosphorylation of PKM2 at Ser 37 then 
involving PTBP1 downregulation and therefore hampering 
PKM2 mRNA alternative splicing.
Summarizing the overall data here reported, we 
describe a novel molecular mechanism of vitamin C that 
presents the Warburg metabolism and related MAPK/ 
EGFR pathway as primary targets of vitamin C in colon 
cancer.
As it is shown in Figure 5, vitamin C (ascorbic 
and dehydroascorbic acid) enters to the cancer cell 
Figure 5: Vitamin C impairs the Warburg effect in KRAS mutant cells through downregulation of GLUT-1 and 
PKM2. A. in absence of vitamin C, PKM2 is phosphorylated at ser 37 and translocates to the cell nucleus. Then, p-PKM2 binds to 
β-catenin and TCF/LEF transcriptional complex promoting c-Myc transcription that, in turn enhances the expression of GLUT-1 and PTB 
that participates in the splicing of PKM2 mRNA. B. vitamin C enters into the cell via GLUT-1 and SVCT1 inducing RAS detachment from 
plasma membrane, blocking downstream phosphorylation of PKM2 phosphorylation at ser 37. Disruption of the transcriptional complex 
formed by p-PKM2, β-catenin and TCF/LEF leads to downregulation of c-Myc, GLUT-1 and PTB expression. Absence of PTB activity 
stalls the splicing of PKM2 mRNA.
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quenching reactive oxygen species (ROS) and therefore 
inducing RAS detachment from plasma membrane. 
As a consequence of RAS mislocation, EGFR/MAPK 
phosphorylation cascade is stalled, thus inhibiting PKM2-
ERK1/2 dependent phosphorylation at Serine 37. Absence 
of p-PKM2 nuclear translocation inhibits GLUT-1 and 
PKM2-PTB dependent expression. The final result is a 
vitamin C selective killing effect in colon cancer cells.
The presented model also raises a provocative 
question: may vitamin C (and / or other molecules 
targeting Warburg key players) open the door for anti-
EGFR therapies in KRAS/BRAF mutant patients? We do 
think that further research and clinical assays addressing 
this query are essential to boost the quest for new 
anticancer strategies.
MATERIALS AND METHODS
Cell culture and cell lines
SW480, LoVo and RKO cells were cultured in 
DMEM supplemented with 10% fetal calf serum (FCS) 
(both from Invitrogen). Cell lines were originally obtained 
from the American Type Culture Collection (ATCC) and 
authenticated using the GenePrint® 10 System (Promega), 
which allows co-amplification and three-color detection of 
ten human loci: TH01, TPOX, WA, Amelogenin, CSF1PO, 
D16S539, D7S820, D13S317, D21S11 and D5S818. Short 
Tandem Repeats profiles were sent for comparison against 
cell line datebases (ATCC, DSMZ). Last test was done 
on February 2015. Immortalized human colonocytes 
(HCEC) were provided by Prof. Manel Esteller IDIBELL 
(Barcelona, Spain).
Antibodies
GLU-1 antibody (1:5000, Millipore, Cat. #: 07-
1401), PKM2 (Ser37) antibody (1:1000, Cell Signaling, 
Cat. 11456), p-ERK1/2 antibody (1: 100, Abcam, Cat. 
ab24157) were employed for immunohistochemistry 
assays.
Anti-Glut-1 antibody (1:200, Abcam, Cat. 
ab137656), MEK1 antibody (1:1000, Abcam, Cat. 
ab96379), ERK1/2 antibody (1:2000, Thermofisher, 
Cat. ERK-7D8), p-ERK1/2 antibody (1:1000, Abcam, 
Cat. ab24157), MAPK (p44/42) antibody (1:500, Cell 
Signaling, Cat. #9102), c-Myc antibody (1:500, Abcam, 
Cat. ab32) and Beta-actin antibody (1:10.000, Cell 
signaling, Cat. #4967) were used for western blot and 
immunofluorescence assays.
Cell viability assays
HCEC, LoVo and SW480 cells were treated 
with pharmacological concentrations of vitamin C (0-
10mM) for 2h, and then replaced with normal DMEM 
supplemented with 10% fetal calf serum (FCS). For 
time dependent viability assays, LoVo and SW480 cells 
were treated withvitamin C (10 mM) for 2h and then 
collected (0, 5, 12, 36 h) for cell counting using a TC20™ 
Automated Cell Counter (Biorad). For cetuximab and 
vitamin C combinatorial assays, HT29 harboring wild 
type KRAS, and the KRAS mutant LoVo and SW480 
were treated with cetuximab (calculated IC50=0,4 μM), 
vitamin C (5mM) alone and combination for 12 hr. Then, 
cells were tripsinized and fixed with trypan blue solution 
(Sigma-Aldrich). Cell counting was carried out using a 
TC20™ Automated Cell Counter (Biorad).
Reactive oxygen species (ROS) measurement
Activity of vitamin C in quenching intracellular 
reactive oxygen species (ROS) was measured using a 
Cellular ROS/Superoxide Detection Assay Kit (Abcam). 
SW480 and LoVo CRC lines were exposed to ascorbate 
(7 mM) and PBS for controls for 20 hr. After treatment, 
cells were washed twice with PBS solution and then 
incubated in medium containing 10 μmol/l H2DCF-
DA at 37°C for 30 minutes. After incubation, cells were 
harvested by trypsinization, and intracellular levels of 
ROS were measured by fluorescence emission with a 
1260 InfinityFluorescence Detector (Agilent). Relative 
intracellular ROS levels after treatment with vitamin C 
were calculated in relation to control, which was given a 
value of 100.
Apoptosis measurements
HCEC, LoVo and SW480 cells were treated with 
vitamin C (10mM) for 2h, and then replaced with normal 
DMEM supplemented with 10% fetal calf serum (FCS). 
1–5 x 105 cells were collected by centrifugation and 
resuspended in 500 μL of 1X binding buffer. Afterwards, 5 
μL of annexin V-FITC and 5 μL of propidium iodide were 
added and incubated for 5 min in the dark. V-FITC binding 
was analyzed by flow cytometry using a BD FACSCanto 
II device (Becton, Dickinson and Company) (Ex = 488 
nm; Em = 350 nm) using FITC signal detector and PI 
staining by the phycoerythrin emission signal detector.
Immunofluorescence assays
For immunofluorescence analyses, cells were rinsed 
once in PBS, fixed in 3.7% paraformaldehyde for 15 min 
at RT and rinsed once in 0.1 M glycine and twice in PBS. 
They were permeabilized in 0.5% Triton X-100 and then 
washed three times in PBS. The non-specific sites were 
blocked by incubation with PBS containing 1% goat serum 
for 30 min at RT. Next, cells were incubated with a rabbit 
or goat polyclonal antibodies against PKM2 (Abcam, 
ab38237), PKM2 (phospho-Ser37) (Signalway Antibody, 
11456), GLUT-1 (Abcam, ab652), SLC23A1 (Abcam, 
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ab112912), PTB (PTBP1, ab5642), Ras antibody [F132-
62] (Abcam, ab16907) and cytokeratine 20diluted in PBS 
for 3 h at RT or overnight at 4°C. After four washes in 
PBS, cells were incubated with secondary antibodies for 
45 min at RT, washed and mounted in VectaShield (Vector 
Laboratories). Confocal microscopy was performed 
with a LSM510 laser scanning microscope (Carl Zeiss) 
equipped with argon (488 nm), HeNe (543 nm) and HeNe 
(633 nm) ion lasers. All confocal scans were acquired 
with the LSM510 software using a Plan Apochromat 
63x NA 1.4 objective (Carl Zeiss). For double or triple 
labeling experiments, images of the same confocal plane 
were sequentially recorded and pseudocolor images were 
generated and superimposed.
Immunohistochemical analysis
Staining of human tissues was performed as 
described (31). The paraffin embedded sections were 
cleared and the sections were incubated with 0.1% 
Pronase (Roche #165 921) in 0.1% CaCl2 pH 7.8. at 37C 
for 10 minutes. They were blocked with 3% H2O2 in 
TBS for 10 mins., washed then blocked with Dako Biotin 
Blocking System (Dako X0590). After washing, they were 
further blocked with 10% Normal Rabbit Serum for 10 
mins at room temperature (RT) and incubated firstly with 
p-ERK (Abcam, ab65142) dilution 1:50, PKM2 (Abcam, 
ab38237) dilution 1:100 and GLUT-1 (Abcam, ab652) 
dilution 1: 100for 1hr at RT, then with biotinylated Rabbit 
Anti-Mouse (Dako, E-0354) at 1/100 for 30 mins. at RT, 
and finally with Strep-ABC complex (Dako, K-0377) at 
1/100 for 30 mins. at RT. The sections were developed 
with AEC substrate kit (vector lab, SK-4200) at RT for 
20 mins., counterstained with haematoxylin and mounted 
with DAKO aqueous mount (Dako, 003181).
Colonosphere formation assay
For the colonosphere formation assay, after 
treatment with different doses of vitamin C for 48 h, cells 
were tripsinized, counted and re-seeded at clonal density 
(1 cell/μl) in 96-well plate with ultra-low attachment 
surface (Costar, Corning, NY, USA) with serum free 
Dulbecco's MEM Nutrient Mixture F+12 Ham medium 
supplemented with 10 ng/ml basic fibroblast growth 
factor, 20 ng/ml epidermal growth factor and 1% v/v 
methylcellulose (R&D Systems, Minneapolis, MN, USA) 
to prevent cell aggregation. The supplements were freshly 
added every 2–3 days and the number and size of formed 
colonospheres were evaluated by optical microscopy 
on day 7 after seeding. Secondary colonospheres were 
formed from the cell population obtained after trypsin-
EDTA disaggregation of primary spheres and seeded at 
clonal density and cultured as described above. To obtain 
a sufficient cell number for secondary colonosphere 
formation, primary colonospheres were seeded for 7 days 
in 6-well ultra-low attachment plates.
Murine assays
SW480 KRAS (G12V) cells were used to generate 
xenograft model in female athymic nude mice Foxn1nu, 
7 weeks old (Harlan Laboratories). Suspensions of 
2x106cells were injected subcutaneously in control and 
experimental mice. Once tumor size volume reached 100 
mm3mice were treated with intraperitoneal (i.p) vehicle 
or vitamin C (4gr/Kg) once daily with the same dosing 
schedule (SW480: n = 10) for 15 days. Tumors were 
measured twice weekly in three perpendicular dimensions 
using a vernier caliper and tumor volume was calculated 
using the ellipsoidal formula V (mm3) = 1/6 π x length 
(mm) x width2 (mm2)
Patients
Formalin-fixed paraffin-embedded 3 μm tissue 
sections from human non-pathological colon (n = 16) 
and small intestine (n = 16), colorectal adenomas (n 
= 76) and primary tumors from metastatic colorectal 
(mCRC) patients (n = 699) were retrieved from 
Fundación Jiménez Díaz Biobank. Tumor specimens 
were retrospectively selected from consecutive 
mCRC patients (1998-2009), which had fulfilled the 
following criteria: adenocarcinoma, metastatic disease, 
no neoadjuvant therapy, available tissue and clinical 
follow up. Clinical data and follow up were collected 
from medical clinical records by medical oncologists. 
The study was approved by the Ethics Committee of the 
institution (PIC 23/2012).
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